2026-2032 Global Daptomycin Industry Research & Trends Analysis Report- YH Research

日本语 | 中文

Home > Reports >Pharma & Healthcare > 2026-2032 Global Daptomycin Industry Research & Trends Analysis Report

2026-2032 Global Daptomycin Industry Research & Trends Analysis Report

Publication Date: 2026-09-10
Report Id: 3155742
Industry: Pharma & Healthcare
Report Page: 133
Chart: 135

PDF Download

Publication Date: 2026-09-10
Report Id: 3155742
Industry: Pharma & Healthcare
Report Page: 133
Chart: 135

PDF Download

A research report provider that focuses on identifying industry pain points and solving core problems for companies！

Table of Contents
Description
Table of Figures
Need a Quote?

1 Market Overview
1.1 Daptomycin Definition
1.2 Global Daptomycin Market Size and Forecast
1.2.1 By Revenue, Global Daptomycin Market Size, 2021-2032
1.2.2 By Sales Volume, Global Daptomycin Market Size, 2021-2032
1.2.3 Global Daptomycin Price Trend, 2021-2032
1.3 China Daptomycin Market Size and Forecast
1.3.1 By Revenue, China Daptomycin Market Size, 2021-2032
1.3.2 By Sales Volume, China Daptomycin Market Size, 2021-2032
1.3.3 China Daptomycin Price Trend, 2021-2032
1.4 China Percentage in Global Market
1.4.1 By Revenue, China Daptomycin Share in Global Market, 2021-2032
1.4.2 By Sales Volume, China Daptomycin Share in Global Market, 2021-2032
1.4.3 Daptomycin Market Size: China VS Global, 2021-2032
1.5 Daptomycin Market Dynamics
1.5.1 Daptomycin Market Drivers
1.5.2 Daptomycin Market Restraints
1.5.3 Daptomycin Industry Trends
1.5.4 Daptomycin Industry Policy

2 Global Competitive Landscape by Company
2.1 Global Daptomycin Revenue by Company, 2021-2026
2.2 Global Daptomycin Sales Volume by Company, 2021-2026
2.3 Global Daptomycin Price by Company, 2021-2026
2.4 Global Daptomycin Participants, Market Position (Tier 1, Tier 2, and Tier 3)
2.5 Global Daptomycin Concentration Ratio
2.6 Global Daptomycin Mergers & Acquisitions, Expansion Plans
2.7 Global Daptomycin Manufacturers Product Type

3 China Competitive Landscape by Company
3.1 China Daptomycin Revenue by Company, 2021-2026
3.2 China Daptomycin Sales Volume by Company, 2021-2026
3.3 China Daptomycin Daptomycin Participants, Market Position (Tier 1, Tier 2, and Tier 3)
3.4 China Daptomycin Market, Sales Percentage of Local Players VS Foreign Players (2021-2026)
3.5 Chinese Local Players, Daptomycin Domestic VS Export
3.6 China Market, Daptomycin Import & Export
3.6.1 China Market, Daptomycin Import & Export, 2021-2032
3.6.2 China Daptomycin Import & Export Trends
3.6.3 Main Sources of China Daptomycin Import
3.6.4 Export Destination of China Daptomycin

4 Daptomycin Production by Region
4.1 Global Daptomycin Capacity, Production and Capacity Utilization, 2021-2032
4.2 Global Geographic Distribution of Daptomycin Manufacturers
4.3 Global Major Manufacturers, Daptomycin Capacity Expansion and Future Plans
4.4 Global Daptomycin Capacity by Region
4.5 Global Daptomycin Production by Region
4.5.1 Global Daptomycin Production & Forecast by Region, 2021 VS 2025 VS 2032
4.5.2 Global Daptomycin Production by Region, 2021-2026
4.5.3 Global Daptomycin Production Market Share & Forecast by Region, 2021-2032

5 Industry Chain Analysis
5.1 Daptomycin Industry Chain
5.2 Daptomycin Upstream Analysis
5.2.1 Daptomycin Core Raw Materials
5.2.2 Main Manufacturers of Daptomycin Core Raw Materials
5.3 Midstream Analysis
5.4 Downstream Analysis
5.5 Daptomycin Production Mode
5.6 Daptomycin Procurement Model
5.7 Daptomycin Industry Sales Model and Sales Channels
5.7.1 Daptomycin Sales Model
5.7.2 Daptomycin Typical Distributors

6 Sights by Purity
6.1 Daptomycin Classification by Purity
6.1.1 ≥99%
6.1.2 <99%
6.2 by Purity, Global Daptomycin Market Size & CAGR, 2021 VS 2025 VS 2032
6.3 by Purity, Global Daptomycin Revenue, 2021-2032
6.4 by Purity, Global Daptomycin Sales Volume, 2021-2032
6.5 by Purity, Global Daptomycin Price, 2021-2032

7 Sights by Manufacturing Technology
7.1 Daptomycin Classification by Manufacturing Technology
7.1.1 Conventional Fed-batch
7.1.2 High-titer Optimized Fermentation
7.2 by Manufacturing Technology, Global Daptomycin Market Size & CAGR, 2021 VS 2025 VS 2032
7.3 by Manufacturing Technology, Global Daptomycin Revenue, 2021-2032
7.4 by Manufacturing Technology, Global Daptomycin Sales Volume, 2021-2032
7.5 by Manufacturing Technology, Global Daptomycin Price, 2021-2032

8 Sights by Customer Business Model
8.1 Daptomycin Classification by Customer Business Model
8.1.1 Independent Generic Injectable Manufacturers
8.1.2 Vertically Integrated Pharmaceutical Groups
8.1.3 Others
8.2 by Customer Business Model, Global Daptomycin Market Size & CAGR, 2021 VS 2025 VS 2032
8.3 by Customer Business Model, Global Daptomycin Revenue, 2021-2032
8.4 by Customer Business Model, Global Daptomycin Sales Volume, 2021-2032
8.5 by Customer Business Model, Global Daptomycin Price, 2021-2032

9 Sights by Finished-dose
9.1 Daptomycin Segment by Finished-dose
9.1.1 500 mg/vial
9.1.2 350 mg/vial
9.2 by Finished-dose, Global Daptomycin Market Size & CAGR, 2021 VS 2025 VS 2032
9.3 by Finished-dose, Global Daptomycin Revenue, 2021-2032
9.4 by Finished-dose, Global Daptomycin Sales Volume, 2021-2032
9.5 by Finished-dose, Global Daptomycin Price, 2021-2032

10 Sales Sights by Region
10.1 By Region, Global Daptomycin Market Size, 2021 VS 2025 VS 2032
10.2 By Region, Global Daptomycin Revenue, 2021-2032
10.3 By Region, Global Daptomycin Sales Volume, 2021-2032
10.4 North America
10.4.1 North America Daptomycin Market Size & Forecasts, 2021-2032
10.4.2 By Country, North America Daptomycin Market Size Market Share
10.5 Europe
10.5.1 Europe Daptomycin Market Size & Forecasts, 2021-2032
10.5.2 By Country, Europe Daptomycin Market Size Market Share
10.6 Asia Pacific
10.6.1 Asia Pacific Daptomycin Market Size & Forecasts, 2021-2032
10.6.2 By Country/Region, Asia Pacific Daptomycin Market Size Market Share
10.7 South America
10.7.1 South AmericaDaptomycin Market Size & Forecasts, 2021-2032
10.7.2 By Country, South America Daptomycin Market Size Market Share
10.8 Middle East & Africa

11 Sales Sights by Country Level
11.1 By Country, Global Daptomycin Market Size & CAGR，2021 VS 2025 VS 2032
11.2 By Country, Global Daptomycin Revenue, 2021-2032
11.3 By Country, Global Daptomycin Sales Volume, 2021-2032
11.4 United States
11.4.1 United States Daptomycin Market Size, 2021-2032
11.4.2 By Company, United States Daptomycin Sales Volume Market Share, 2025
11.4.3 by Purity, United States Daptomycin Market Size, Share, 2025 VS 2032
11.4.4 by Finished-dose, United States Daptomycin Market Size, Share, 2025 VS 2032
11.5 Europe
11.5.1 Europe Daptomycin Market Size, 2021-2032
11.5.2 By Company, Europe Daptomycin Sales Volume Market Share, 2025
11.5.3 by Purity, Europe Daptomycin Market Size, Share, 2025 VS 2032
11.5.4 by Finished-dose, Europe Daptomycin Market Size, Share, 2025 VS 2032
11.6 China
11.6.1 China Daptomycin Market Size, 2021-2032
11.6.2 By Company, China Daptomycin Sales Volume Market Share, 2025
11.6.3 by Purity, China Daptomycin Market Size, Share, 2025 VS 2032
11.6.4 by Finished-dose, China Daptomycin Market Size, Share, 2025 VS 2032
11.7 Japan
11.7.1 Japan Daptomycin Market Size, 2021-2032
11.7.2 By Company, Japan Daptomycin Market Share, 2025
11.7.3 by Purity, Japan Daptomycin Market Size, Share, 2025 VS 2032
11.7.4 by Finished-dose, Japan Daptomycin Market Size, Share, 2025 VS 2032
11.8 South Korea
11.8.1 South Korea Daptomycin Market Size, 2021-2032
11.8.2 By Company, South Korea Daptomycin Market Share, 2025
11.8.3 by Purity, South Korea Daptomycin Market Size, Share, 2025 VS 2032
11.8.4 by Finished-dose, South Korea Daptomycin Market Size, Share, 2025 VS 2032
11.9 Southeast Asia
11.9.1 Southeast Asia Daptomycin Market Size, 2021-2032
11.9.2 By Company, Southeast Asia Daptomycin Market Share, 2025
11.9.3 by Purity, Southeast Asia Daptomycin Market Size, Share, 2025 VS 2032
11.9.4 by Finished-dose, Southeast Asia Daptomycin Market Size, Share, 2025 VS 2032
11.10 India
11.10.1 India Daptomycin Market Size, 2021-2032
11.10.2 By Company, India Daptomycin Market Share, 2025
11.10.3 by Purity, India Daptomycin Market Size, Share, 2025 VS 2032
11.10.4 by Finished-dose, India Daptomycin Market Size, Share, 2025 VS 2032
11.11 Middle East & Africa
11.11.1 Middle East & Africa Daptomycin Market Size, 2021-2032
11.11.2 By Company, Middle East & Africa Daptomycin Market Share, 2025
11.11.3 by Purity, Middle East & Africa Daptomycin Market Size, Share, 2025 VS 2032
11.11.4 by Finished-dose, Middle East & Africa Daptomycin Market Size, Share, 2025 VS 2032

12 Manufacturers Profile
12.1 Olon
12.1.1 Olon Company Information, Head Office, Market Area, and Industry Position
12.1.2 Olon Daptomycin Models, Specifications, and Application
12.1.3 Olon Daptomycin Sales Volume, Revenue, Price and Gross Margin, 2021-2026
12.1.4 Olon Company Profile and Main Business
12.1.5 Olon Recent Developments
12.2 Xellia Pharmaceuticals
12.2.1 Xellia Pharmaceuticals Company Information, Head Office, Market Area, and Industry Position
12.2.2 Xellia Pharmaceuticals Daptomycin Models, Specifications, and Application
12.2.3 Xellia Pharmaceuticals Daptomycin Sales Volume, Revenue, Price and Gross Margin, 2021-2026
12.2.4 Xellia Pharmaceuticals Company Profile and Main Business
12.2.5 Xellia Pharmaceuticals Recent Developments
12.3 Livzon Group Fuzhou Fuxing Pharmaceutical
12.3.1 Livzon Group Fuzhou Fuxing Pharmaceutical Company Information, Head Office, Market Area, and Industry Position
12.3.2 Livzon Group Fuzhou Fuxing Pharmaceutical Daptomycin Models, Specifications, and Application
12.3.3 Livzon Group Fuzhou Fuxing Pharmaceutical Daptomycin Sales Volume, Revenue, Price and Gross Margin, 2021-2026
12.3.4 Livzon Group Fuzhou Fuxing Pharmaceutical Company Profile and Main Business
12.3.5 Livzon Group Fuzhou Fuxing Pharmaceutical Recent Developments
12.4 Huadong Medicine
12.4.1 Huadong Medicine Company Information, Head Office, Market Area, and Industry Position
12.4.2 Huadong Medicine Daptomycin Models, Specifications, and Application
12.4.3 Huadong Medicine Daptomycin Sales Volume, Revenue, Price and Gross Margin, 2021-2026
12.4.4 Huadong Medicine Company Profile and Main Business
12.4.5 Huadong Medicine Recent Developments
12.5 Zhejiang Hisun Pharmaceutical
12.5.1 Zhejiang Hisun Pharmaceutical Company Information, Head Office, Market Area, and Industry Position
12.5.2 Zhejiang Hisun Pharmaceutical Daptomycin Models, Specifications, and Application
12.5.3 Zhejiang Hisun Pharmaceutical Daptomycin Sales Volume, Revenue, Price and Gross Margin, 2021-2026
12.5.4 Zhejiang Hisun Pharmaceutical Company Profile and Main Business
12.5.5 Zhejiang Hisun Pharmaceutical Recent Developments
12.6 Zhejiang Medicine
12.6.1 Zhejiang Medicine Company Information, Head Office, Market Area, and Industry Position
12.6.2 Zhejiang Medicine Daptomycin Models, Specifications, and Application
12.6.3 Zhejiang Medicine Daptomycin Sales Volume, Revenue, Price and Gross Margin, 2021-2026
12.6.4 Zhejiang Medicine Company Profile and Main Business
12.6.5 Zhejiang Medicine Recent Developments
12.7 Chongqing Daxin Pharmaceutical
12.7.1 Chongqing Daxin Pharmaceutical Company Information, Head Office, Market Area, and Industry Position
12.7.2 Chongqing Daxin Pharmaceutical Daptomycin Models, Specifications, and Application
12.7.3 Chongqing Daxin Pharmaceutical Daptomycin Sales Volume, Revenue, Price and Gross Margin, 2021-2026
12.7.4 Chongqing Daxin Pharmaceutical Company Profile and Main Business
12.7.5 Chongqing Daxin Pharmaceutical Recent Developments
12.8 Lunan New Times Biotechnology
12.8.1 Lunan New Times Biotechnology Company Information, Head Office, Market Area, and Industry Position
12.8.2 Lunan New Times Biotechnology Daptomycin Models, Specifications, and Application
12.8.3 Lunan New Times Biotechnology Daptomycin Sales Volume, Revenue, Price and Gross Margin, 2021-2026
12.8.4 Lunan New Times Biotechnology Company Profile and Main Business
12.8.5 Lunan New Times Biotechnology Recent Developments
12.9 Sichuan Novals Pharmaceuticals
12.9.1 Sichuan Novals Pharmaceuticals Company Information, Head Office, Market Area, and Industry Position
12.9.2 Sichuan Novals Pharmaceuticals Daptomycin Models, Specifications, and Application
12.9.3 Sichuan Novals Pharmaceuticals Daptomycin Sales Volume, Revenue, Price and Gross Margin, 2021-2026
12.9.4 Sichuan Novals Pharmaceuticals Company Profile and Main Business
12.9.5 Sichuan Novals Pharmaceuticals Recent Developments
12.10 Fujian Comhony Biotechnology
12.10.1 Fujian Comhony Biotechnology Company Information, Head Office, Market Area, and Industry Position
12.10.2 Fujian Comhony Biotechnology Daptomycin Models, Specifications, and Application
12.10.3 Fujian Comhony Biotechnology Daptomycin Sales Volume, Revenue, Price and Gross Margin, 2021-2026
12.10.4 Fujian Comhony Biotechnology Company Profile and Main Business
12.10.5 Fujian Comhony Biotechnology Recent Developments
12.11 Suzhou Biosynergy Pharmaceutical
12.11.1 Suzhou Biosynergy Pharmaceutical Company Information, Head Office, Market Area, and Industry Position
12.11.2 Suzhou Biosynergy Pharmaceutical Daptomycin Models, Specifications, and Application
12.11.3 Suzhou Biosynergy Pharmaceutical Daptomycin Sales Volume, Revenue, Price and Gross Margin, 2021-2026
12.11.4 Suzhou Biosynergy Pharmaceutical Company Profile and Main Business
12.11.5 Suzhou Biosynergy Pharmaceutical Recent Developments
12.12 North China Pharmaceutical
12.12.1 North China Pharmaceutical Company Information, Head Office, Market Area, and Industry Position
12.12.2 North China Pharmaceutical Daptomycin Models, Specifications, and Application
12.12.3 North China Pharmaceutical Daptomycin Sales Volume, Revenue, Price and Gross Margin, 2021-2026
12.12.4 North China Pharmaceutical Company Profile and Main Business
12.12.5 North China Pharmaceutical Recent Developments

13 Conclusion

14 Appendix
14.1 Research Methodology
14.2 Data Source
14.2.1 Secondary Sources
14.2.2 Primary Sources
14.3 Market Estimation Model
14.4 Disclaimer

According to YH Research, the global market for Daptomycin should grow from US$ 71.25 million in 2025 to US$ 116 million by 2032, with a CAGR of 6.9% for the period of 2026-2032.

In 2025, global Daptomycin capacity 5 Tons, sales reached approximately 4.5 Tons, with an average market price of around 14,890 USD/Kg, industrial gross margin 28%.

Daptomycin

According to YH Research, the global market for Daptomycin should grow from US$ 71.25 million in 2025 to US$ 116 million by 2032, with a CAGR of 6.9% for the period of 2026-2032.

Unit: US$ M

www.yhresearch.com

In-depth insight into market trends

Daptomycin is a cyclic lipopeptide antibacterial positioned in the high-value, low-tonnage segment of the anti-infective API industry, where process control and regulatory continuity matter materially more than nominal manufacturing scale. The molecule has the formula C₇₂H₁₀₁N₁₇O₂₆ and a molecular weight of approximately 1,620.7 Da; its antibacterial activity is driven by calcium-dependent insertion into Gram-positive bacterial membranes, rapid membrane depolarization, and subsequent arrest of DNA, RNA and protein synthesis. The relevant industrial market is pharmaceutical-grade API or drug substance rather than finished 350 mg or 500 mg injectable vials, laboratory reagents, analytical standards or fermentation intermediates. Commercial API programs are typically positioned in the high-98% to ≥99% HPLC purity range, but pharmaceutical suitability is governed by a broader specification covering individual and total related substances, residual solvents, water, microbiological attributes and stability. Storage is process- and registration-specific: validated commercial supply chains may use refrigerated conditions of 2–8°C or frozen storage around −20°C, while registered products can carry shelf lives of approximately three years. These requirements make stability data, cold-chain control and manufacturing-change discipline integral to commercial qualification rather than secondary logistics considerations.

The manufacturing platform is built around controlled microbial fermentation followed by a purification train that is substantially more demanding than conventional small-molecule API synthesis. Industrial production uses Streptomyces roseosporus fermentation with controlled fatty-acid precursor feeding, followed by broth clarification, adsorption, ion-exchange chromatography, hydrophobic-interaction or reversed-phase chromatography, membrane concentration and final crystallization or lyophilization. Cost competitiveness is determined by strain productivity, precursor-feed control, impurity formation, chromatographic selectivity, resin productivity and downstream recovery rather than fermenter volume alone. Structurally related lipopeptide congeners are difficult to separate, and incremental purity improvement can require disproportionate resin, solvent and product-loss penalties. As a result, process development is moving upstream: preventing unwanted analogues during fermentation is economically preferable to removing them through additional chromatography. The supply chain therefore extends beyond conventional fermentation nutrients to specialized resins, membrane systems, high-purity solvents, analytical instrumentation and validated clean utilities. Downstream customers are sterile-injectable manufacturers, and supplier onboarding commonly involves analytical comparability, stability packages, quality-system audits, regulatory-file access, validation batches and formal change-control arrangements.

Demand is anchored in serious Gram-positive infections rather than broad outpatient antibiotic use, which gives the product a resilient but clinically bounded commercial profile. Approved applications include complicated skin and skin-structure infections and Staphylococcus aureus bloodstream infections, including right-sided infective endocarditis. Typical adult regimens include 4 mg/kg every 24 hours for cSSSI and 6 mg/kg every 24 hours for S. aureus bacteremia, with extended dosing intervals in severe renal impairment. Daptomycin is not indicated for pneumonia, which materially limits the addressable clinical setting relative to several broad-spectrum agents. The United States remains one of the most established commercial markets because of early adoption and a mature generic injectable ecosystem, while Europe combines stable institutional demand with stringent GMP and dossier requirements. Japan and other regulated Asian markets place strong emphasis on supplier consistency and change control. China is distinct because it combines a large fermentation-API manufacturing base with an expanding domestic generic-injectable market; inclusion of daptomycin injection in national volume-based procurement has increased the importance of API cost efficiency, forecast reliability and diversified qualified sourcing for finished-dose manufacturers.

Competition is led by a relatively small group of technically experienced anti-infective manufacturers in Europe and China, with regulatory reach and impurity-control capability serving as the primary differentiators. Xellia Pharmaceuticals manufactures the API in Budapest and supports U.S. and European regulatory dossiers, while ACS Dobfar supplies Daptomycin Drug Substance from its Italian anti-infective platform. In China, representative producers include Livzon Group Fuzhou Fuxing Pharmaceutical, Zhejiang Hisun Pharmaceutical, Zhejiang Medicine and the Huadong Medicine manufacturing system, alongside specialized suppliers such as Chongqing Daxin Pharmaceutical and Sichuan Novals Pharmaceuticals. Recent competitive activity is increasingly vertical rather than purely capacity-driven. Zhejiang Medicine’s controlled subsidiary Changhai Pharmaceutical obtained domestic approval for daptomycin API in 2023 after regulatory and FDA-related site work, and Zhejiang Medicine subsequently received Chinese approval for a 0.5 g daptomycin injectable in August 2024 after cumulative R&D spending of approximately RMB15.2 million on the formulation program. The move extends the company from drug-substance production into finished-dose commercialization. In parallel, Huadong Medicine’s manufacturing platform filed a 2024 patent covering high-purity daptomycin crystal preparation, emphasizing shorter purification, lower solvent consumption and industrial scalability, illustrating how process intensification is becoming a competitive asset.

Growth will be shaped by generic penetration, higher-purity API migration, second-source qualification and supply-chain resilience rather than unrestricted expansion in antibiotic consumption. On the demand side, persistent treatment needs for resistant Gram-positive infections support a stable clinical base, while antimicrobial stewardship and therapeutic alternatives such as vancomycin, linezolid and newer anti-MRSA agents cap volume elasticity. On the technology side, strain improvement, precision precursor feeding, online fermentation monitoring, selective chromatography, resin reuse and membrane-based concentration offer the clearest path to lower unit cost without compromising quality. Supply strategies are also changing: flexible multiproduct fermentation sites combined with dedicated critical purification steps and geographically diversified regulatory files are more attractive than large standalone daptomycin lines. Competitive advantage will increasingly reside with manufacturers able to support China, the United States, Europe and selected Asian markets from stable processes and harmonized dossiers. For Chinese suppliers, the most defensible opportunities are higher-purity grades, regulated-market second-source programs, domestic generic-injectable expansion and selective API-to-FDF integration; the principal constraints remain the narrow clinical scope, long customer-validation cycles, environmental-compliance costs, structural spare capacity and trade-policy uncertainty.

Report Scope
This report aims to provide a comprehensive study of the global market for Daptomycin. Report Highlights:
(1) Global Daptomycin market size (sales volume & revenue), history data from 2021-2025, and forecast data from 2026 to 2032.

(2) Global Daptomycin market competitive situation, sales, revenue, price, and market share, from 2021 to 2026.

(3) China Daptomycin market competitive situation, sales, revenue, price, and market share, from 2021 to 2026.

(4) Global Daptomycin segment by region (or country), key regions cover the United States, Europe, China, Japan, South Korea, Southeast Asia, and India, etc.

(5) Global Daptomycin segment by Purity, and by Finished-dose, and regional segment by Purity, and by Finished-dose.

(6) Global major production regions of Daptomycin, capacity, production and trends.

(7) Daptomycin industry supply chain, upstream, midstream, and downstream analysis.

Market Segmentation
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Market segment by Purity, covers
    ≥99%
    <99%

Market segment by Manufacturing Technology, covers
    Conventional Fed-batch
    High-titer Optimized Fermentation

Market segment by Customer Business Model, covers
    Independent Generic Injectable Manufacturers
    Vertically Integrated Pharmaceutical Groups
    Others

Market segment by Finished-dose, can be divided into
    500 mg/vial
    350 mg/vial

Market segment by players, this report covers
    Olon
    Xellia Pharmaceuticals
    Livzon Group Fuzhou Fuxing Pharmaceutical
    Huadong Medicine
    Zhejiang Hisun Pharmaceutical
    Zhejiang Medicine
    Chongqing Daxin Pharmaceutical
    Lunan New Times Biotechnology
    Sichuan Novals Pharmaceuticals
    Fujian Comhony Biotechnology
    Suzhou Biosynergy Pharmaceutical
    North China Pharmaceutical